Edition:
United Kingdom

Oxford Immunotec Global PLC (OXFD.OQ)

OXFD.OQ on NASDAQ Stock Exchange Global Market

14.27USD
15 Dec 2017
Change (% chg)

$0.52 (+3.78%)
Prev Close
$13.75
Open
$13.75
Day's High
$14.52
Day's Low
$13.75
Volume
227,739
Avg. Vol
39,624
52-wk High
$19.50
52-wk Low
$12.20

Summary

Name Age Since Current Position

Richard Sandberg

74 2008 Independent Chairman of the Board

Peter Wrighton-Smith

42 2002 Chief Executive Officer, Director

Richard Altieri

57 2012 Chief Financial Officer

Stefan Linn

51 2017 Chief Operating Officer

Peter Edwardson

52 2017 Senior Vice President & Head of Blood Screening

Elizabeth Keiley

51 2015 Vice President, General Counsel

Jeff Schroeder

55 2013 Chief Commercial Officer

Richard Wenstrup

64 2017 Chief Medical Officer

Ronald Andrews

57 2015 Director

Patrick Balthrop

60 2016 Director

Patricia Randall

66 2014 Director

Andrew Walton

50 2015 Director

Herman Rosenman

70 2013 Independent Director

Stephen Spotts

62 2010 Independent Director

James Tobin

72 2014 Independent Director

Biographies

Name Description

Richard Sandberg

Mr. Richard A. Sandberg serves as an Independent Chairman of the Board of the company. He has played a principal role in starting and building a number of medical diagnostic companies including that of founder, chairman, chief executive officer, and chief financial officer of DIANON Systems Inc., a publicly traded oncology diagnostics company that was a pioneer in marketing new diagnostic technologies as a service rather than a product offering. He also served as chairman and chief financial officer of Lifecodes Corporation, a pioneer in DNA testing technology; chief financial officer and director of Matritech, Inc., a publicly traded biotechnology company specializing in proteomic diagnostic products for the early detection of a variety of cancers; and as chief financial officer of Critical Diagnostics, Inc., a company specializing in developing new diagnostic tests for cardiology. He has also served as a director of North American Scientific Inc., a publicly held developer and marketer of radiation therapy products and systems for treating breast and prostate cancer, from 2005 to 2009; as a director of Ethan Allen Interiors Inc., an international manufacturer and retailer of fine home furnishings, from 2003 to 2009; and serves as chairman of two privately held diagnostic companies. Mr. Sandberg earned his Bachelors degree in Business from Northwestern University and a Masters in Business Administration from Harvard University.

Peter Wrighton-Smith

Dr. Peter Wrighton-Smith serves as a Chief Executive Officer and Director of Oxford Immunotec Global PLC. He has held both positions since founding Oxford Immunotec in 2002. Before founding Oxford Immunotec, Dr. Wrighton-Smith held senior positions with PowderJect Pharmaceuticals PLC, now part of Chiron Corporation, including senior projects director, a business development role, and managing director of PowderJect Diagnostics Ltd., a subsidiary of PowderJect engaged in the development of cellular immune based diagnostics. During his tenure with PowderJect, the company became a global vaccines business with more than 1,000 employees. Dr. Wrighton-Smith has a Masters in Engineering, Economics & Management, and a Doctorate in Medical Engineering, both from Oxford University.

Richard Altieri

Mr. Richard M. Altieri serves as a Chief Financial Officer of Oxford Immunotec Global PLC. Mr. Altieri is our Chief Financial Officer, a position he has held since joining us in January 2012. Before joining the Company, from July 2007 through December 2011, Mr. Altieri was vice president and chief financial officer of Salient Surgical Technologies, Inc., a medical technology company that developed and marketed surgical advanced energy products. From 2004 to 2007, Mr. Altieri was senior vice president of finance and chief financial officer of Straumann USA, a global leader in the field of implant dentistry and dental tissue regeneration. Earlier in his career, beginning in 1992, Mr. Altieri was vice president and chief financial officer of Mitek Surgical Products, Inc., which was acquired by Johnson & Johnson in 1995. Following the acquisition, Mr. Altieri continued to oversee the financial operations of DePuy Mitek as vice president – finance through 2004. Mr. Altieri earned his Bachelors degree in Accounting from Northeastern University and his Masters in Business Administration from Babson College.

Stefan Linn

Mr. Stefan C. Linn is Chief Operating Officer of the Company. Mr. Linn joined IMS Health from TPG Capital, where he worked with TPG's healthcare and consumer portfolio companies to drive operating improvements. Prior to joining TPG, Mr. Linn was a Senior Vice President at McKesson Corporation, where he was responsible for marketing strategy, product development and customer programs. During his tenure at McKesson, Mr. Linn also served as President of Health Mart, and oversaw McKesson's consumer products division, packaging business RxPack, and the McKesson Patient Relationship Solutions division. Earlier in his career, Mr. Linn was a Vice President at Merck-Medco Managed Care, LLC, and also worked for McKinsey & Company. He holds a B.A. in Economics from the University of Dallas and an M.B.A. from the University of California at Berkeley.

Peter Edwardson

Dr. Peter Edwardson, Ph.D. is Senior Vice President & Head of Blood Screening of the company. Dr. Edwardson has been our Chief Operations Officer since October 2013, overseeing our operations worldwide, including all manufacturing, research and development activities, quality assurance and regulatory affairs and laboratory operations. Prior to becoming our Chief Operations Officer, Dr. Edwardson served as General Manager of our operations in the United Kingdom, with primary responsibility for all manufacturing and research and development activities. Dr. Edwardson joined Oxford Immunotec in 2008 and has over 20 years of experience in the medical device industry in both small start-up companies and large corporations. Immediately before joining Oxford Immunotec, from 2003 to 2008, Dr. Edwardson was vice president of medical technologies for Prometic Biosciences Ltd., a subsidiary of Prometic Life Sciences Inc., which designed, developed, manufactured and commercialized affinity adsorbents sold to biopharmaceutical companies for use in their drug manufacturing processes. From 1999 to 2003, he served as technical director at Tayside Flow Technologies and Tissuemed Ltd, two start-up companies focused on development and commercialization of implantable devices. Dr. Edwardson earned his Bachelors degree in Biochemistry and Physiology from Leeds University and his Doctorate from Cambridge University.

Elizabeth Keiley

Ms. Elizabeth M. Keiley serves as a Vice President, General Counsel, of the company a position she has held since January 1, 2015. Ms. Keiley joined the Company in September 2012 as Associate General Counsel. She was promoted to Vice President, General Counsel effective January 1, 2015 and in this role has responsibility for all of our legal affairs. Before joining us, from July 2008 to March 2012, Ms. Keiley was Assistant General Counsel, Americas of Zimmer, Inc., a subsidiary of Zimmer Holdings, Inc., the world’s largest orthopedic device manufacturer. Before working at Zimmer, Ms. Keiley was a trial lawyer and partner with Wildman, Harrold, Allen & Dixon in Chicago, Illinois where she represented clients in a wide variety of commercial disputes and transactions. Ms. Keiley earned her Bachelors degree in Psychology/Philosophy from Boston College and her Juris Doctor from Loyola University School of Law.

Jeff Schroeder

Mr. Jeff R. Schroeder is no longer a Chief Commercial Officer of the Company effective January 1, 2018. Mr. Schroeder has been Chief Commercial Officer since October 2013, overseeing worldwide sales and marketing operations. Prior to becoming Chief Commercial Officer, Mr. Schroeder served as our President, North America from February 2007 to October 2013, overseeing sales and marketing operations in the United States. Before joining Oxford Immunotec, from 2002 to 2007, he served as vice president of sales, breast health and vice president of marketing at Cytyc Corporation, which manufactured and sold tests used in the diagnosis of cervical cancer and other women’s health-related illnesses and merged with Hologic Corporation in 2007. Before working at Cytyc, from 2000 to 2002, Mr. Schroeder was vice president, sales and marketing for CytoLogix Corporation, a cellular diagnostics company. Earlier in his career, from 1984 to 2000, Mr. Schroeder held various sales positions with increasing levels of responsibility for the diagnostics division of Abbott Laboratories, ultimately becoming director of worldwide marketing for the division. Mr. Schroeder earned his Bachelors degree from Southeast Missouri State University.

Richard Wenstrup

Mr. Richard Wenstrup, M.D., serves as Chief Medical Officer of the Company. Dr. Wenstrup brings to Oxford Immunotec more than 20 years of clinical leadership experience, including over a decade within the diagnostics industry. Most recently, Dr. Wenstrup served as Executive Vice President, Chief Medical Officer, for Myriad Genetics, Inc., where he played a key leadership role and made substantial contributions across the company that helped drive and support a multi-fold increase in revenue over a decade. In addition to building and leading Myriad's clinical and medical affairs teams, Dr. Wenstrup was actively involved in the company's product development, M&A, and in-licensing activities. He also previously served as Chief Medical Officer for Myriad Genetic Laboratories, Inc. Prior to joining Myriad Genetics, Dr. Wenstrup served as a tenured Professor of Pediatrics (Human Genetics) at Cincinnati Children's Hospital Medical Center and as a tenured Professor of Biomedical Engineering at the University of Cincinnati. During his time in academia, Dr. Wenstrup was principal investigator on multiple research grants from the National Institutes of Health (NIH) and the FDA Orphan Products Grant Program. He also served as a standing member of NIH review committees and on the scientific advisory boards of several disease-related foundations. Dr. Wenstrup was the founding director of the Molecular Diagnostics Laboratory at Cincinnati Children's Hospital and co-founder of Assurex Health, Inc., now a subsidiary of Myriad Genetics, Inc.

Ronald Andrews

Mr. Ronald A. Andrews, Jr. serves as a Director of the Company. Mr. Andrews most recently served as President of the Genetic Sciences Division of Thermo Fisher Scientific, a position he assumed upon Thermo Fisher’s acquisition of Life Technologies Corporation, where he had been the President of the Medical Sciences Venture. Following the acquisition, Mr. Andrews led the integration of Life Technologies’ next generation sequencing technology into the Thermo Fisher product line. Prior to that, Mr. Andrews served as Chief Executive Officer of GE Molecular Diagnostics, a position he assumed upon GE’s acquisition of Clarient Inc., a NASDAQ-listed oncology-focused clinical laboratory service company, at which Mr. Andrews had been serving as Chief Executive Officer. He is currently a member of the Board of Governors of CancerLinQ LLC, a wholly-owned non-profit subsidiary of the American Society of Clinical Oncology and a member of the Board of the Mission Hospital Foundation. Mr. Andrews earned his Bachelor’s degree from Wofford College.

Patrick Balthrop

Mr. Patrick J. Balthrop, Sr. serves as a Director of Oxford Immunotec Global PLC. Most recently, Mr. Balthrop served as President and CEO of Luminex Corporation (Nasdaq: LMNX) from 2004 to 2014, during which time the company’s revenues grew eightfold. During his tenure at Luminex, Mr. Balthrop implemented innovative R&D programs which led to the development and subsequent successful commercialization of a long list of new products, oversaw multiple significant acquisitions and drove a 66% gross margin improvement. Before joining Luminex, Mr. Balthrop served as President of Fisher Healthcare, which is now a division of Thermo Fisher Scientific, Inc., where he was responsible for the successful turnaround of a $1 billion integrated healthcare products manufacturing and distribution business. Prior to that, Mr. Balthrop held multiple positions at Abbott Laboratories, where he played an integral part in the development and global commercialization of a number of high profile diagnostic products. Mr. Balthrop holds an M.B.A. from the Kellogg Graduate School of Management, Northwestern University and a B.S. from Spring Hill College. He currently serves as a Director at Personalis and NextGxDx, as an advisor to Water Street Healthcare Partners and Warburg Pincus, and as the Founding Principal at Apalachee Ventures.

Patricia Randall

Ms. Patricia Randall serves as a Director of the company. Ms. Randall joined Oxford Immunotec in 2008 and has responsibility for legal affairs. Ms. Randall has more than 35 years of experience as a lawyer and advisor to both public and private companies in a wide range of industries. Before joining Oxford Immunotec, from 2003 to 2008, Ms. Randall served as vice president, general counsel and secretary of Matritech, Inc., a biotechnology company specializing in proteomic diagnostic products for the early detection of a variety of cancers. Before joining Matritech, she served as vice president and general counsel of Hadco Corporation, a global manufacturer of printed circuit boards, and as vice president and general counsel of Robotic Vision Systems, Inc., a leading supplier of machine vision technologies. In November 2004, more than twenty months after Ms. Randall’s departure from Robotic Vision Systems, Inc., that company filed a petition under the federal bankruptcy laws. Ms. Randall earned her Bachelors degree from American University in Philosophy and her Juris Doctor from Northeastern University School of Law.

Andrew Walton

Mr. Andrew Scott Walton serves as a Director of the Company. Mr. Walton is currently the Chief Executive Officer of Ameritox, a company that offers laboratory testing and practice management tools to help clinicians coordinate and optimize the care of chronic pain and behavioral health patients. Prior to Ameritox, he held senior leadership positions within LabCorp, most recently as Executive Vice President of the esoteric testing business and a member of LabCorp’s five-person Executive Committee. Before leading the esoteric businesses at LabCorp, Mr. Walton had numerous roles with the company including heading up strategic planning and mergers & acquisitions, and serving as the company’s Chief Information Officer. Mr. Walton earned his Bachelor’s degree from Yale University and a Master of Business Administration degree from the Harvard Business School.

Herman Rosenman

Mr. Herman Rosenman CPA serves as an Independent Director of the Company. Mr. Rosenman served as senior vice president, finance and chief financial officer of Gen-Probe Incorporated, a publicly traded molecular diagnostics company, from 2001 through the sale of that company to Hologic, Inc. in August 2012. From 1997 to 2000, Mr. Rosenman served as president and chief executive officer of Ultra Acquisition Corp., a manufacturer and parts retailer. From 1994 to 1997, he served as president and chief executive officer of RadNet Management, Inc., a healthcare provider. He has also served as chief financial officer of Rexene Corp. and was an audit partner at Coopers & Lybrand (now PricewaterhouseCoopers LLP). Mr. Rosenman currently serves as a member of the board of directors and audit committee chairman of Vivus, Inc., a publicly traded biopharmaceutical company, Medistem, Inc., a stem cell therapy company, and BioFire Diagnostics, Inc., a molecular diagnostics company, as well as an advisory board member of Scripps Clinics/Green Hospital, a large healthcare provider in San Diego, CA. Previously, he has served on numerous public and private company boards of directors, frequently as a member of the company’s audit committee, including ARYx Therapeutics, Infinity Pharmaceuticals, Inc., Emphasys Medical, Inc. and Discovery Partners International, Inc. Mr. Rosenman is a certified public accountant who received a B.B.A. in finance and accounting from Pace University and a Masters in Business Administration in finance from the Wharton School of the University of Pennsylvania.

Stephen Spotts

Mr. Stephen L. Spotts serves as an Independent Director of Oxford Immunotec Global PLC. Mr. Spotts is a Director, a position he has held since November 2010. Mr. Spotts is chief executive officer, president, director and founder of ProTom International, Inc., a medical technology company focused on proton therapy for cancer patients founded in 2007. Before founding ProTom, from 2000 to 2006, Mr. Spotts was president, chief executive officer, and a member of the board of directors of Pathology Partners, Inc. (now known as Miraca Life Sciences, Inc.). From 2005 through mid-2008, he served on the board of directors of Genoptix, Inc., a California-based, publicly traded specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists (Genoptix, Inc. was acquired by Novartis AG in 2011). Mr. Spotts earned his Bachelors degree in Business Administration from the University of Mississippi.

James Tobin

Mr. James R. Tobin serves as an Independent Director of the Company, Mr. Tobin served as President and Chief Executive Officer of Boston Scientific from March 1999 to July 2009 during which time the company’s revenues grew from more than $2 billion to over $8 billion. During his tenure, Boston Scientific achieved a number of significant milestones, including the successful commercial launch of numerous products, significant acquisitions and strategic alliances (including the transformative acquisition of Guidant Corporation), and the growth of Boston Scientific’s international business to more than 40% of the company’s annual revenues. Before joining Boston Scientific, Mr. Tobin served as President and CEO of Biogen Idec Inc., where he was instrumental in making it one of the world’s most successful biotechnology companies. Prior to that, Mr. Tobin was an executive with Baxter International. He became President and Chief Operating Officer of Baxter in 1992 and was responsible for all operations of the $9 billion company. Mr. Tobin holds an M.B.A. from Harvard Business School and an A.B. from Harvard College.